ZEPZELCA Specialised Therapeutics Pharma Pty Ltd
Product name
ZEPZELCA
Accepted date
Jun-2025
Active ingredients
lurbinectedin
Proposed indication
ZEPZELCA is for the maintenance treatment of extensive-stage small cell lung cancer (SCLC) in adult patients whose disease has not progressed after initial therapy.
Application type
C (new indication)
Publication date
Jun-2025
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.